赖氨酰氧化酶介导VEGF诱导的人牙髓细胞分化与血管生成
本研究探讨重组人血管内皮生长因子(rhVEGF)对人牙髓细胞(HDPCs)成牙本质分化、体外血管生成及赖氨酰氧化酶(LOX)表达与活性的影响,并与rhFGF-2比较。结果显示rhVEGF通过调控LOX表达促进细胞生长、成牙潜能和体外血管生成,提示其在再生牙髓治疗中的潜在益处。
要点
- rhVEGF促进HDPCs细胞生长、ALP活性和矿化结节形成,效果优于rhFGF-2。
- rhVEGF上调LOX及LOXL mRNA表达和胺氧化酶活性,并促进血管生成基因表达和毛细血管样形成。
- 抑制LOX或沉默LOX/LOXL基因可减弱rhVEGF诱导的上述效应及Akt、ERK、JNK、p38磷酸化和NF-κB活化。
核心结论
- rhVEGF通过调控LOX表达促进HDPCs细胞生长、成牙潜能和体外血管生成,支持其在再生牙髓治疗中的潜在应用。
研究设计与样本
- 使用pBAD-HisA质粒在大肠杆菌中构建rhVEGF,HDPCs经1-50 μg mL-1 rhVEGF处理14天,并与rhFGF-2比较。
- 检测ALP活性、茜素红染色矿化结节、成牙/成骨标志物mRNA、信号通路蛋白表达,数据采用ANOVA与Bonferroni检验(α=0.05)。
主要发现
- rhVEGF显著增加细胞生长(P<0.05)、ALP活性(P<0.05)和矿化结节形成,并上调成骨/成牙标志物mRNA表达,效果优于rhFGF-2。
- rhVEGF显著增加胺氧化酶活性(P<0.05),上调LOX和LOXL mRNA表达,并剂量依赖性上调血管生成基因mRNA和毛细血管样形成,程度大于rhFGF-2。
- BAPN抑制LOX或RNA干扰沉默LOX/LOXL基因可减弱rhVEGF诱导的生长、ALP活性、矿化、标志物mRNA表达和体外血管生成。
- rhVEGF诱导Akt、ERK、JNK和p38磷酸化及NF-κB活化,该效应可被LOX/LOXL沉默或BAPN抑制。
临床怎么用
- rhVEGF可能通过LOX依赖途径促进牙髓细胞成牙分化和血管生成,为再生牙髓治疗提供潜在策略。
- LOX/LOXL及下游Akt、ERK、JNK、p38和NF-κB通路可能成为调控靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To investigate the effects of recombinant human vascular endothelial growth factor (rhVEGF) on odontoblastic differentiation, in vitro angiogenesis, and expression and activity of lysyl oxidase (LOX) in human dental pulp cells (HDPCs), compared with rhFGF-2. To identify the underlying molecular mechanisms, the study focused on whether LOX was responsible for the actions of rhVEGF. METHODOLOGY: Recombinant human vascular endothelial growth factor (rhVEGF) was constructed using the pBAD-HisA plasmid in Escherichia coli. HDPCs were treated with 1-50 μg mL-1 rhVEGF for 14 days. Alkaline phosphatase (ALP) activity was measured, and the formation of calcified nodules was assessed using alizarin red staining after the induction of odontogenic differentiation of HDPCs. The expression level of the odontogenic differentiation markers was detected by reverse transcription polymerase chain reaction. Signal pathways were assessed by Western blot and immunocytochemistry. The data were analysed by anova with Bonferroni's test (α = 0.05). RESULTS: Recombinant human vascular endothelial growth factor significantly increased cell growth (P < 0.05), ALP activity (P < 0.05) and mineralization nodule formation and upregulated the mRNA expression levels of the osteogenic/odontogenic markers that were lower with rhFGF-2. rhVEGF significantly increased amine oxidase activity (P < 0.05) and upregulated LOX and LOXL mRNA expression in HDPCs. Additionally, rhVEGF dose-dependently upregulated angiogenic gene mRNAs and capillary tube formation to a greater degree than rhFGF-2. Inhibition of LOX using β-aminopropionitrile (BAPN) and LOX or LOXL gene silencing by RNA interference attenuated rhVEGF-induced growth, ALP activity, mineralization, the expression of marker mRNAs and in vitro angiogenesis. Furthermore, treatment with rhVEGF resulted in phosphorylation of Akt, ERK, JNK and p38, and activation of NF-κB, which was inhibited by LOX or LOXL silencing and BAPN. CONCLUSION: Recombinant human vascular endothelial growth factor promoted cell growth, odontogenic potential and in vitro angiogenesis via modulation of LOX expression. These results support the concept that rhVEGF may offer therapeutic benefits in regenerative endodontics.
引用
- Bae WJ, Yi JK, Park J, et al. Lysyl oxidase-mediated VEGF-induced differentiation and angiogenesis in human dental pulp cells. Int Endod J. 2017. PMID: 28568134. doi:10.1111/iej.12796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。